Nanotechnology Now - Press Release: "Nanoviricides® Anti-Ebola Results Presented at Annual Meeting of the American Society for Virology by USAMRIID Scientist"

Home > Press > Nanoviricides® Anti-Ebola Results Presented at Annual Meeting of the American Society for Virology by USAMRIID Scientist

Abstract:
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company") reports that the results of the evaluation of several of its nanoviricides® anti-Ebola agents were presented July 17th at the Annual Meeting of the American Society for Virology, July 17-21, at Montana State University, Bozeman, MT. Dr. Corinne Scully delivered the presentation, which was entitled "Polymeric Micelle Nanomaterials as Antiviral Compounds For Ebola Virus Infection."

Nanoviricides® Anti-Ebola Results Presented at Annual Meeting of the American Society for Virology by USAMRIID Scientist

West Haven, CT | Posted on July 19th, 2010

The studies were performed in the laboratory of Dr. Gene Olinger at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Frederick, MD.

In cell culture screening assays, the nanoviricides® were evaluated for cytotoxicity and for inhibition of Ebola virus infection. Several of the nanoviricides demonstrated a dose-dependent inhibition of Ebola virus infectivity with no toxicity of uninfected cells at concentrations that were effective against the virus.

A subset of the nanoviricides that were effective in cell culture was selected for testing in vivo in a mouse model of Ebola infection. The compounds were well tolerated by the animals and showed some efficacy against the mouse-adapted Ebola virus. Efficacy of nanoviricides treatment against Ebola virus was demonstrated by an increase in lifespan in this uniformly 100% lethal animal model.

The Company developed a library of chemical ligands that were expected to bind to the Ebola virus envelope proteins. The results reported at this meeting will help guide the synthesis of next generation anti-Ebola nanoviricides in a lead optimization synthetic program. Optimized nanoviricides will also be evaluated against other similar Hemorrhagic Fever Viruses, e.g. Marburg virus.

Based on the current results and previous success with another hemorrhagic fever virus (viz. Dengue), the Company believes that it can develop a single nanoviricide drug that is highly effective against both Ebola and Marburg filoviruses. Developing a single drug against the various Ebola and Marburg viruses has been a major challenge for researchers in the field. Currently there are no approved vaccines or therapeutics for the prevention or treatment of Ebola and Marburg viruses.

Ebola/Marburg viruses are a major concern both as potential global health threats and as potential threat agents for Biosecurity and Biodefense, and are identified as Category A agents. Ebola outbreaks have resulted in fatality rates as high as 80% in humans

www.who.int/mediacentre/factsheets/fs103/en/index.html

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

####

About Nanoviricides
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

About USAMRIID
USAMRIID, located at Fort Detrick, Maryland, is the lead medical research laboratory for the U.S. Department of Defense's Biological Defense Research Program, and plays a key role in national defense and in infectious disease research. The Institute conducts basic and applied research on biological threats resulting in medical solutions (such as vaccines, drugs and diagnostics) to protect the warfighter. While USAMRIID’s primary mission is focused on the military, its research often has applications that benefit society as a whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical Research and Materiel Command. For more information, visit www.usamriid.army.mil

The information contained in this press release does not necessarily reflect the position or the policy of the Government and no official endorsement should be inferred.

For more information, please click here

Contacts:
NanoViricides, Inc.
Amanda Schuon
310-550-7200

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: